Eton Pharmaceuticals, Inc.

For the period ended Dec 31, 2024. Filed Mar 18, 2025.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 18, 2025

ETON$64.35+14.0%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Balance Sheets

(in thousands, except share and per share amounts)

	December 31,	December 31,
	2024	2023
Assets
Current assets:
Cash and cash equivalents	$14,936	$21,388
Accounts receivable, net	5,361	3,411
Inventories, net	15,232	911
Prepaid expenses and other current assets	5,492	1,129
Total current assets	41,021	26,839
Property and equipment, net	34	58
Intangible assets, net	34,881	4,739
Operating lease right-of-use assets, net	175	92
Other long-term assets, net	12	12
Total assets	$76,123	$31,740
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$4,167	$1,848
Current portion of long-term debt, net of discount	—	5,380
Accrued Medicaid rebates	6,866	3,627
Accrued liabilities	8,914	5,386
Total current liabilities	19,947	16,241
Long-term debt, net of discount and including accrued fees	29,811	—
Operating lease liabilities, net of current portion	107	22
Other long-term liabilities	1,830	—
Total liabilities	51,695	16,263
Commitments and contingencies (Note 15)
Stockholders’ equity
Common stock, $0.001 par value; 50,000,000 shares authorized; 26,709,084 and 25,688,062 shares issued and outstanding at December 31, 2024 and 2023, respectively	27	26
Additional paid-in capital	132,294	119,521
Accumulated deficit	(107,893)	(104,070)
Total stockholders’ equity	24,428	15,477
Total liabilities and stockholders’ equity	$76,123	$31,740

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.